Sionna Therapeutics, Inc./$SION

13:30
09:10
04:45
00:25
20:00
1D1W1MYTD1Y5YMAX

About Sionna Therapeutics, Inc.

Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefit to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.

Ticker

$SION
Primary listing

Industry

Biotechnology

Employees

48

SION Metrics

BasicAdvanced
$739M
-
-$6.81
-
-

Bulls say / Bears say

Sionna Therapeutics reported positive Phase 1 data for its NBD1 stabilizers SION-719 and SION-451, indicating both compounds were well tolerated and achieved desired pharmacokinetic targets, supporting their potential as add-ons to standard cystic fibrosis treatments. (sionnatx.com)
The company completed an upsized IPO in February 2025, raising approximately $219 million in gross proceeds, bolstering its financial position to support ongoing and future clinical developments. (biospace.com)
Analysts at Guggenheim initiated coverage on Sionna Therapeutics with a 'buy' rating and a $45.00 price target, suggesting significant upside potential from the current stock price. (americanbankingnews.com)
Sionna Therapeutics reported a net loss of $16.5 million for the first quarter of 2025, reflecting ongoing expenses associated with its clinical-stage programs. (sionnatx.com)
The company's reliance on successful clinical outcomes for its NBD1 stabilizers poses a risk; any setbacks in clinical trials could negatively impact investor confidence and stock performance. (sionnatx.com)
Despite positive analyst coverage, the stock has experienced volatility, with a 52-week range between $13.20 and $25.19, indicating potential instability in investor sentiment. (americanbankingnews.com)
Data summarised monthly by Lightyear AI. Last updated on 11 Jul 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $SION

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs